Top 5 Life Science Startup Investors in Portugal

Last updated: Apr 2024 A list of 5 angel investors and VC funds that invest in Life science startups based in Portugal. We rank investors based on the number of investments they made in Life science companies from Portugal. We update this investor list every month.

Top 5 Life Science Startup Investors in Portugal

Investor	Life Science Portugal investments
Caixa Capital	2
Artesian VC	1
Nina Capital	1
Social Impact Fund	1
Shilling	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Caixa Capital is the Private Equity and Venture Capital arm of banking Group Caixa Geral de Depósitos and has a track record spanning over two decades of activity, since the industry was created in Portugal. It is a leading investor in terms of funds under management, portfolio size and diversity.Caixa Capital´s mission is to invest in fundsand companies, led by highly qualified management teams, with high growth and valuation potential, that enable our funds to achieve an attractive risk adjusted return and for society at large to benefit sustainably from our activity.Currently with more than 700 million Euros under management and a portfolio of over 80 investments, Caixa Capital is a reference in this area with special links to the respective European sector associations.

Investment focus

Software, Information Technology, SaaS
Seed, Series A, Funding Round
Portugal, United States, Spain

Portfolio highlights

HiJiffy — Increase direct bookings and upselling with HiJiffy's AI-powered communication solutions for hospitality.
Probely — Probely is a web application and API vulnerability scanner for agile teams. Automate Security Testing by adding Probely into your SDLC and CI/CD pipelines.
Infraspeak — Infraspeak is an Intelligent CMMS Software that brings outstanding flexibility, connectivity and intelligence to your operations.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Series A, Pre-Seed
Australia, United States, Hong Kong

Portfolio highlights

Sitemate — Sitemate builds user friendly software which thousands of industrial companies use every day to streamline their paperwork and processes.
Braingaze — Braingaze solves major challenges around cognitive disorders of the brain. We use a patented neuro-biomarker based on small involuntary eye movements. These are triggered by functional games, the resulting signal is analysed using algorithms trained by Deep Learning based on actual real patient / control cases. We adress pre-symptomatic stagesof Alzheimer's disease and the most common child cognitive disorder ADHD. Our tools are on the market and covered by a CE Mark as a medical device. Our pipeline includes detection / diagnostic tools as well as digital therapy solutions that have shown to reduce symtoms by over 50%.
Navi Medical Technologies — Navi Medical Technologies is a medical device development company.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Ryver — We provide software to generate synthetic medical images and assess their privacy as well as quality
CryoCloud — CryoCloud Accelerate your protein structure determination - Bring your cryo-EM data analysis to the next level by using our cloud-based image analysis workflow.
Zetta Genomics — Zetta Genomics unleashes the power of genomic data to improve health outcomes for millions of patients around the world - and realise the potential of

Shilling is an early-stage venture capital firm backing exceptional founders from the start.Shilling invests in a wide range of verticals and seeks out the biggest opportunities across all B2B and consumer categories. Leveraging the concept of Founder LPs, Shilling brings much more than capital and offers through its Shilling Platform, directaccess to successful founders and executives of leading companies. This platform supports entrepreneurs in validating and developing their ventures, which then accelerate their growth into global markets.